140 related articles for article (PubMed ID: 21272176)
1. The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2008: analysis of the Victorian Admitted Episodes Dataset.
Lingaratnam S; Thursky KA; Slavin MA; Kirsa SW; Bennett CA; Worth LJ
Intern Med J; 2011 Jan; 41(1b):121-9. PubMed ID: 21272176
[TBL] [Abstract][Full Text] [Related]
2. Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Australian Consensus Guidelines 2011 Steering Committee.
Lingaratnam S; Slavin MA; Koczwara B; Seymour JF; Szer J; Underhill C; Prince M; Mileshkin L; O'Reilly M; Kirsa SW; Bennett CA; Davis ID; Morrissey O; Thursky KA;
Intern Med J; 2011 Jan; 41(1b):75-81. PubMed ID: 21272171
[TBL] [Abstract][Full Text] [Related]
3. An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009.
Lingaratnam S; Slavin MA; Mileshkin L; Solomon B; Burbury K; Seymour JF; Sharma R; Koczwara B; Kirsa SW; Davis ID; Prince M; Szer J; Underhill C; Morrissey O; Thursky KA
Intern Med J; 2011 Jan; 41(1b):110-20. PubMed ID: 21272175
[TBL] [Abstract][Full Text] [Related]
4. Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care.
Courtney DM; Aldeen AZ; Gorman SM; Handler JA; Trifilio SM; Parada JP; Yarnold PR; Bennett CL
Oncologist; 2007 Aug; 12(8):1019-26. PubMed ID: 17766662
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic treatment of febrile episodes in neutropenic cancer patients. Clinical and economic considerations.
de Lalla F
Drugs; 1997 May; 53(5):789-804. PubMed ID: 9129866
[TBL] [Abstract][Full Text] [Related]
6. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of direct medical costs of hospitalization for febrile neutropenia.
Lathia N; Mittmann N; DeAngelis C; Knowles S; Cheung M; Piliotis E; Shear N; Walker S
Cancer; 2010 Feb; 116(3):742-8. PubMed ID: 20029970
[TBL] [Abstract][Full Text] [Related]
8. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
Jarque I; Sanz MA
Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
[TBL] [Abstract][Full Text] [Related]
9. Episodes of fever and neutropenia in children with cancer in a tertiary care medical center in Turkey.
Tezcan G; Kupesiz A; Ozturk F; Ogunc D; Gultekin M; Yesilipek A; Hazar V
Pediatr Hematol Oncol; 2006; 23(3):217-29. PubMed ID: 16517538
[TBL] [Abstract][Full Text] [Related]
10. A cancer and neutropenia database study.
Hewitt A
Can J Oncol; 1994 Jul; 4(3):277-84. PubMed ID: 7529629
[TBL] [Abstract][Full Text] [Related]
11. Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012.
Tai E; Guy GP; Dunbar A; Richardson LC
J Oncol Pract; 2017 Jun; 13(6):e552-e561. PubMed ID: 28437150
[TBL] [Abstract][Full Text] [Related]
12. Etiology and clinical course of febrile neutropenia in children with cancer.
Hakim H; Flynn PM; Knapp KM; Srivastava DK; Gaur AH
J Pediatr Hematol Oncol; 2009 Sep; 31(9):623-9. PubMed ID: 19644403
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre.
Schelenz S; Giles D; Abdallah S
Ann Oncol; 2012 Jul; 23(7):1889-93. PubMed ID: 22048152
[TBL] [Abstract][Full Text] [Related]
14. [The costs of hospital infections in a group of patients in a tertiary-care hospital].
Juárez-Muñoz IE; Vázquez-Rodríguez A; Games-Eternood J; Sciandra-Rico M; Mercado-Arellano JA; Solórzano-Santos F
Gac Med Mex; 1999; 135(5):457-62. PubMed ID: 10596485
[TBL] [Abstract][Full Text] [Related]
15. A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment.
Lingaratnam S; Worth LJ; Slavin MA; Bennett CA; Kirsa SW; Seymour JF; Dalton A; Koczwara B; Prince HM; O'Reilly M; Mileshkin L; Szer J; Thursky KA
Aust Health Rev; 2011 Nov; 35(4):491-500. PubMed ID: 22126955
[TBL] [Abstract][Full Text] [Related]
16. Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee.
Tam CS; O'Reilly M; Andresen D; Lingaratnam S; Kelly A; Burbury K; Turnidge J; Slavin MA; Worth LJ; Dawson L; Thursky KA;
Intern Med J; 2011 Jan; 41(1b):90-101. PubMed ID: 21272173
[TBL] [Abstract][Full Text] [Related]
17. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.
Caggiano V; Weiss RV; Rickert TS; Linde-Zwirble WT
Cancer; 2005 May; 103(9):1916-24. PubMed ID: 15751024
[TBL] [Abstract][Full Text] [Related]
18. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection.
Santolaya ME; Alvarez AM; Avilés CL; Becker A; Cofré J; Cumsille MA; O'Ryan ML; Payá E; Salgado C; Silva P; Tordecilla J; Varas M; Villarroel M; Viviani T; Zubieta M
J Clin Oncol; 2004 Sep; 22(18):3784-9. PubMed ID: 15365075
[TBL] [Abstract][Full Text] [Related]
19. Costs attributable to healthcare-acquired infection in hospitalized adults and a comparison of economic methods.
Roberts RR; Scott RD; Hota B; Kampe LM; Abbasi F; Schabowski S; Ahmad I; Ciavarella GG; Cordell R; Solomon SL; Hagtvedt R; Weinstein RA
Med Care; 2010 Nov; 48(11):1026-35. PubMed ID: 20940650
[TBL] [Abstract][Full Text] [Related]
20. Early hospital discharge versus continued hospitalization in febrile pediatric cancer patients with prolonged neutropenia: A randomized, prospective study.
Ahmed N; El-Mahallawy HA; Ahmed IA; Nassif S; El-Beshlawy A; El-Haddad A
Pediatr Blood Cancer; 2007 Nov; 49(6):786-92. PubMed ID: 17366527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
